5,6-dimethoxy-1-methyl-1H-indole-2-carboxylic acid | 380607-13-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 5,6-dimethoxy-1-methyl-1H-indole-2-carboxylic acid
• 英文别名: 5,6-dimethoxy-1-methylindole-2-carboxylic acid
• CAS: 380607-13-6
• 化学式: C₁₂H₁₃NO₄
• mdl: MFCD03848061
• 分子量: 235.24
• InChiKey: ANSUPYBJVNMSJB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  60.7
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  5,6-dimethoxy-1-methyl-1H-indole-2-carboxylic acid 在 三溴化硼 作用下， 以 二氯甲烷 为溶剂， 生成 5,6-二羟基-1-甲基-1H-吲哚-2-羧酸
  参考文献：
  名称：

  Synthesis and Agonistic Activity at the GPR35 of 5,6-Dihydroxyindole-2-carboxylic Acid Analogues

  摘要：

  5,6-Dihydroxyindole-2-carboxylic acid (DHICA), an intermediate of melanin synthesis and an eumelanin building block, was recently discovered to be a GPR35 agonist with moderate potency. Here, we report the synthesis and pharmacological characterization of a series of DHICA analogues against GPR35 using both label-free, dynamic mass redistribution and Tango beta-arrestin translocation assays. This led to identification of novel GPR35 agonists with improved potency and/or having biased agonism.

  DOI：

  10.1021/ml300076u
• 作为产物：
  描述：

  5,6-二甲氧基吲哚-2-甲酸 在 lithium hydroxide monohydrate 、 potassium carbonate 作用下， 以 四氢呋喃 、 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 49.5h， 生成 5,6-dimethoxy-1-methyl-1H-indole-2-carboxylic acid
  参考文献：
  名称：

  From Far West to East: Joining the Molecular Architecture of Imidazole-like Ligands in HO-1 Complexes

  摘要：

  HO-1过度表达已被报道在多种人类恶性肿瘤中。不幸的是，在大多数这些情况下，报道了糟糕的临床结果，因此HO-1的抑制被认为是一种有价值且经过验证的抗癌方法。为了寻找适合作为HO-1抑制剂的新型化合物，我们在这里报告了一种基于片段的方法，其中使用了配体连接实验。将HO-1抑制剂的经典结构的两个最重要的部分作为起点，生成了1000种新型化合物，并通过结构和配体基础方法进行了虚拟评估。连接实验使我们得到了一系列新型的吲哚基化合物。设计了八种选择分子的合成途径，并合成了这些化合物。生物活性显示，一些分子达到了微摩尔活性，而分子4d以1.03μM的IC50抑制了HO-1。这项研究表明，我们的连接方法是成功的，并生成了一种新型的命中化合物。这些结果正在进行进一步的开发。

  DOI：

  10.3390/ph14121289

文献信息

• Intramolecular N-acyliminium ion versus Friedel–Crafts cyclization onto 3-indoles: synthesis of the novel rings pyrrolizino[2,1-b]indole and homologues
  作者：Raffaella Cincinelli、Sabrina Dallavalle、Lucio Merlini、Raffaella Nannei、Leonardo Scaglioni

  DOI：10.1016/j.tet.2009.02.036

  日期：2009.4

  γ-oxoamides causes Friedel–Crafts intramolecular cyclization to β-carbolinones and dihydro-2H-azepino[3,4-b]indol-1-ones, in contrast to secondary δ-,ɛ-, and ζ-oxoamides, which cyclize to the novel heterocyclic rings pyrrolizino[2,1-b]indole, indolizino[2,1-b]indole, and 9a,11-diaza-indeno[1,2-a]azulene, via an intermediate N-acyliminium ion. Tertiary amides lead only the Friedel–Crafts ring closure, thus

  吲哚-2-羧酸β-和γ-氧代酰胺的酸处理导致Friedel-Crafts分子内环化为β-咔啉酮和二氢-2 H-氮杂环庚烷[3,4- b ]吲哚-1-酮，与仲δ相反-，ɛ-和ζ-氧代酰胺，可环化成新型杂环吡咯并[2,1- b ]吲哚，吲哚并[2,1- b ]吲哚和9a，11-二氮杂茚并[1,2-通过中间的N-酰基亚胺离子形成α ] azulene。叔酰胺仅导致Friedel-Crafts环闭合，从而允许合成更大的稠合环。
• Intramolecular Friedel-Crafts Reaction of Indoles with Carbonyl Groups: A Simple Synthesis of 3- and 4-Substituted β-Carbolin-1-ones
  作者：Sabrina Dallavalle、Raffaella Cincinelli、Lucio Merlini

  DOI：10.1055/s-2008-1072613

  日期：2008.5

  The intramolecular Friedel-Crafts reaction of indole-2-carboxylic acid β-oxoamides catalyzed by trifluoroacetic acid or InCl 3 , is a convenient method for the synthesis of 3-aryl-, 4-aryl-, and 4-alkyl-β-carbolin-1-ones.

  三氟乙酸或InCl 3 催化吲哚-2-羧酸β-氧代酰胺的分子内Friedel-Crafts反应是合成3-芳基-、4-芳基-和4-烷基-β-咔啉的便捷方法-1个。
• 1,3-SUBSTITUTED CYCLOALKYL DERIVATIVES HAVING ACIDIC, MOSTLY HETEROCYCLIC GROUPS, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS
  申请人：Goerlitzer Jochen

  公开号：US20080249126A1

  公开（公告）日：2008-10-09

  The invention relates to 1,3-substituted cycloalkyl derivatives having acidic, mostly heterocyclic groups and to their physiologically acceptable salts and physiologically functional derivatives. What is described are compounds of the formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved.

  本发明涉及具有酸性、大多数为杂环基团的1,3-取代环烷衍生物及其生理上可接受的盐和生理上功能性衍生物。所描述的是式I的化合物，其中基团如定义所述，以及它们的生理上可接受的盐和制备它们的方法。这些化合物适用于治疗和/或预防脂肪酸代谢紊乱和葡萄糖利用紊乱以及涉及胰岛素抵抗的紊乱。
• ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS
  申请人：Yamagishi Tatsuya

  公开号：US20120232052A1

  公开（公告）日：2012-09-13

  The present invention relates to aryl carboxamide derivatives of formula (I), wherein Ar 1 is phenyl; Ar 2 is aryl; n is 1-4; X is —O—, —S—, —SO— or —SO 2 —, a prodrug thereof or a pharmaceutically acceptable salt thereof, which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of such disorders and diseases as pain in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases as pain in which voltage gated sodium channels are involved.

  本发明涉及公式（I）的芳基羧酰胺衍生物，其中Ar1是苯基；Ar2是芳基；n为1-4；X为—O—、—S—、—SO—或—SO2—，其前体药物或其药学上可接受的盐，具有阻断电压门控钠通道如TTX-S通道的活性，并在治疗或预防涉及电压门控钠通道的疾病和疾病，如疼痛方面中有用。本发明还涉及包含这些化合物的制药组合物以及这些化合物和组合物在预防或治疗涉及电压门控钠通道的疾病和疾病，如疼痛方面的使用。
• Synthesis, Modeling, and RET Protein Kinase Inhibitory Activity of 3- and 4-Substituted β-Carbolin-1-ones
  作者：Raffaella Cincinelli、Giuliana Cassinelli、Sabrina Dallavalle、Cinzia Lanzi、Lucio Merlini、Maurizio Botta、Tiziano Tuccinardi、Adriano Martinelli、Sergio Penco、Franco Zunino

  DOI：10.1021/jm8007823

  日期：2008.12.25

  A series of beta-carbolin-2-ones and 3,10-dihydro-2H-azepino[3,4-b]indol-1-ones have been designed, synthesized, and evaluated as RET protein kinase inhibitors oil the basis Of their Structural similarity with the prototype indolin-2-one RPI-1. Some beta-carbolin-2-ones (structure 2) showed ail ability to inhibit RET enzymatic activity in vitro and proliferation of RETC634R oncogene-transformed NIH3T3 cells comparable to that of the reference compound. The docking analysis of the interaction of these compounds with the crystallographic structure of RET tyrosine kinase domain suggested a new binding interaction scheme different from the one proposed during their design. The rigid structure of the compounds of this series represents a new scaffold with potential advantages in the design of RET protein kinase inhibitors.